Versant Ventures VI GP, L.P.
CIK 1777654 · last filed 2025-09-23
Versant Ventures VI GP, L.P. is a corporate insider who has filed 7 SEC Form 4 insider transactions across 5 companies since 2020. The most recent filing shows the insider sold $24.4M of LVTX on Sep 23, 2025. Across all open-market trades the lifetime net is −$34.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $57.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$57.01M
5
7
-$33.97M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LAVA Therapeutics NV (LVTX) Delisted | 10%+ Owner | 0 | $1.74 | $0 | -$24.41M | 1 | 2025-09-23 |
| IPSC | 10%+ Owner | 12,530,909 | $2.25 | $28.19M | -$31.00M | 2 | 2022-08-11 |
| Repare Therapeutics Inc. (RPTX) Delisted | 10%+ Owner | 0 | $2.65 | $0 | $0 | 1 | 2021-01-19 |
| PASG | 10%+ Owner | 4,959,769 | $5.81 | $28.82M | $28.35M | 1 | 2020-03-03 |
| Akero Therapeutics, Inc. (AKRO) Delisted | 10%+ Owner | 3,118,638 | $54.65 | $170.43M | -$6.91M | 2 | 2020-01-21 |
Recent Filings
7 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-09-23 | LAVA Therapeutics NV (LVTX) Delisted | Sell (S) | −17,420,418 | -$24.41M | EDGAR |
| 2022-08-11 | IPSC | Mixed | −5,488,800 | -$43.00M | EDGAR |
| 2021-06-23 | IPSC | Mixed | +63,900,636 | $12.00M | EDGAR |
| 2021-01-19 | Repare Therapeutics Inc. (RPTX) Delisted | Other (J) | −5,000,000 | $0 | EDGAR |
| 2020-03-03 | PASG | Mixed | +34,718,383 | $28.35M | EDGAR |
| 2020-01-21 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −178,596 | -$3.73M | EDGAR |
| 2020-01-09 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −159,171 | -$3.18M | EDGAR |